Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06344052 · ClinicalTrials.gov registry record · Phase 2

To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

A Phase 2 study of Basal Cell Carcinoma, sponsored by Stamford Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
80
Enrollment target
10
Study locations

NCT06344052 is a Phase 2 study of Basal Cell Carcinoma that is actively recruiting participants, run by Stamford Pharmaceuticals. The registered enrollment target is 80 participants, below the 101-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (21% lower). The trial reports 10 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06344052, a Phase 2 study of Basal Cell Carcinoma, is actively recruiting participants, sponsored by Stamford Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
80 participants
Enrollment target
10
Study locations

Study Summary

The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an add-on to hedgehog pathway inhibitor therapy. Researchers will compare the objective response rate for treated Basal cell carcinoma tumors between 3 treatment Arms. * Arm 1 participants will receive daily hedgehog pathway inhibitor, and 3 cycles of SP-002 treatment. * Arm 2 participants will receive daily hedgehog pathway inhibitor, and 1 cycle of SP-002 treatment. * Arm 3 participants will receive daily hedgehog pathway inhibitor only.

Conditions Studied

Basal Cell Carcinoma

Interventions

  • DRUG Vismodegib
  • DRUG SP-002

Study Locations (10)

Florida

  • Research Site - Boca Raton
  • Research Site - Coral Springs
  • Research Site - Cutler Bay

Texas

  • Research Site - Cedar Park
  • Research Site - Humble
  • Research Site - Longview

Arizona

  • Research Site - Phoenix

Maryland

  • Research Site - Rockville

Missouri

  • Research Site - Lee's Summit

New York

  • Research Site - Rochester

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-04-09
Est. Completion 2029-03-30
Phase Phase 2

Sponsor

Stamford Pharmaceuticals

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06344052

The ClinicalTrials.gov registry entry for NCT06344052 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (21% lower). The listed sponsor is Stamford Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Basal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Vismodegib is the first listed.

NCT06344052 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Florida, Texas, Arizona.

Frequently Asked Questions

What is clinical trial NCT06344052 about?

NCT06344052 is a clinical study titled "To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma". The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an ...

What is the current status of trial NCT06344052?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-04-09. Estimated completion is 2029-03-30.

What conditions does trial NCT06344052 study?

This clinical trial studies the following conditions: Basal Cell Carcinoma.

What interventions are being tested in trial NCT06344052?

The interventions under investigation include: Vismodegib (DRUG), SP-002 (DRUG).

Who is sponsoring clinical trial NCT06344052?

This trial is sponsored by Stamford Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06344052 being conducted?

This trial has 10 study locations across Arizona, Florida, Maryland, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Basal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Basal Cell Carcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.